ChinaAMC Hang Seng Biotech ETF (03069.HK) Falls 2.33% Intraday as Hong Kong Pharma Stocks Slip

NewTimeSpace News: As of 9:48 on November 3, the ChinaAMC Hang Seng Biotech ETF (03069.HK) fell 2.33% to a latest price of HK$13.830. The ETF has traded 2.0237 million units so far today for a turnover of HK$27.9565 million at an average price of HK$13.815, with a turnover rate of 1.12%. It is down 3.15% so far this week. Its current net asset value per unit is HK$14.1303, and its assets under management stand at HK$2.563 billion.

(Note on scope: the net asset value per unit and assets under management are as of November 2, 2026; the week-to-date change is measured against the closing price of HK$14.280 on October 30.)

On the news front, Hong Kong pharmaceutical stocks fell in early trade on November 3, with the WuXi group retreating across the board: WuXi XDC dropped 3.86% to HK$63.50, WuXi AppTec 3.72% to HK$173.30, WuXi Biologics 1.66% to HK$43.86 and Akeso 2.92% to HK$76.60, while GenScript Biotech fell nearly 5%. In the prior session on November 2, Hong Kong stocks rebounded overall—the Hang Seng Index gained 0.42% and the Hang Seng TECH Index 2.25%—yet innovative drug names moved against the trend, with Akeso down more than 3% that day. For last week (October 26 to 30), the Hang Seng Biotech Index fell 2.80% and the Hang Seng Healthcare Index 2.76%, smaller declines than the Hang Seng TECH Index's 3.02% but well behind the Hang Seng Index's 0.87% gain. On the industry side, the US marketing application for sac-TMT, a TROP2 ADC developed by Kelun-Biotech and partnered with Merck, has been accepted by the FDA with priority review for advanced or recurrent endometrial cancer previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors, with a PDUFA date of June 15, 2027.

The ChinaAMC Hang Seng Biotech ETF (03069.HK) is a passively managed exchange-traded fund under China Asset Management (Hong Kong), with the investment objective of closely tracking the performance of the Hang Seng Biotech Index. Compiled by Hang Seng Indexes Company on a net total return basis, the index reflects the overall performance of the 30 largest biotech companies listed in Hong Kong that are eligible for Southbound trading, including pre-revenue companies listed under Chapter 18A of the Listing Rules; its constituents span the Hang Seng Industry Classification System sub-sectors of biotechnology, pharmaceuticals, pharmaceutical distribution, pharmaceutical and biotech contract services, and medical devices and supplies, weighted by freefloat-adjusted market capitalisation with a 10% cap on any single constituent.

AJ Securities believes the US filing marks a key step in the drug's global commercialisation—it is sac-TMT's first marketing application overseas and the first time a Chinese-origin antibody-drug conjugate has been filed in the United States. The filing is based on the global Phase III TroFuse-005 study, which showed that sac-TMT monotherapy extended median progression-free survival from 3.9 to 7.2 months, cutting the risk of progression or death by 41%, and median overall survival from 12.1 to 19.0 months, cutting the risk of death by 32%—making it the first global Phase III TROP2 ADC study to achieve dual overall and progression-free survival benefits in PD-(L)1-pretreated endometrial cancer. Kelun-Biotech originated the drug and licensed rights outside Greater China to Merck in May 2022; four indications are already approved in China.